Bio-Marker Composition for Prediction of Drug for lung cancer Sensitivity Estimation Method for Prediction of Drug for lung cancer Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug for lung cancer Sensitivity

The present invention relates to a biomarker composition for determining lung cancer drug reactivity. In the biomarker composition composed of a combination of markers containing a variation that modulates gene expression for determining the reactivity to a lung cancer drug, the biomarker compositio...

Full description

Saved in:
Bibliographic Details
Main Authors LEE SUN HO, CHOI ICWON, JUNG, JONG SUN, HONG JONG HUI
Format Patent
LanguageEnglish
Korean
Published 20.05.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a biomarker composition for determining lung cancer drug reactivity. In the biomarker composition composed of a combination of markers containing a variation that modulates gene expression for determining the reactivity to a lung cancer drug, the biomarker composition for determining lung cancer drug reactivity comprises 2_217847583_C_T (marker 1), 2_71424561_G_GT (marker 2), 2_217847883_G_A (marker 3), 2_217848003_A_G (marker 4), and 17_81206909_A_C (marker 5). According to the present invention, through biomarkers for drugs related to lung cancer, it is possible to predict the susceptibility of each target genotype for a lung cancer drug, and thus effective preliminary verification is conducted not only in the field of personalized medicine but also in the discovery of new drug candidates. 본 발명은 폐암 약물 반응성 판단을 위한 바이오 마커 조성물에 관한 것으로, 본 발명은 폐암 약물에 대한 반응성 판단을 위하여, 유전자 발현을 조절하는 변이가 포함된 마커들의 조합으로 구성되는 바이오 마커 조성물에 있어서, 상기 바이오 마커 조성물은, 2_217847583_C_T(마커1), 2_71424561_G_GT(마커2), 2_217847883_G_A(마커3), 2_217848003_A_G(마커4) 및 17_81206909_A_C(마커5)를 포함하여 구성되는 폐암 약물 반응성 판단을 위한 바이오 마커 조성물을 포함한다. 이와 같은 본 발명에 의하면, 본 발명에서는 폐암 관련 약물들에 대한 바이오 마커들을 통해, 폐암 약물에 대하여, 대상자 유전형질별 민감성을 예측할 수 있으므로, 개인별 맞춤의학 분야뿐만 아니라 신약 후보군 발굴에 효과적인 예비검증이 이루어지도록 하는 효과가 있다.
Bibliography:Application Number: KR20190098525